Loading
Oncotherapy Solutions
Oncotherapy Solutions is a Seattle company developing peptide drug conjugates: small peptides that carry a cell-killing drug to tumour cells. Its lead, OTS-P22, is being prepared for triple-negative breast cancer.
Also called: Oncotherapy Solutions, LLC
Overview
Oncotherapy Solutions, LLC develops peptide drug conjugates and bispecific drug conjugates for drug-resistant and metastatic solid tumours. Its most advanced preclinical candidate, OTS-P22, targets a receptor that the company says is highly expressed in many solid tumours; the company reports that a single intravenous dose inhibited tumour growth in an HCC1806 triple-negative breast cancer mouse model, and plans IND-enabling studies for triple-negative breast, metastatic ovarian and endometrial cancers. A 2026 National Cancer Institute SBIR award funds a lead peptide drug conjugate for triple-negative breast cancer; its abstract describes conjugates aimed at the luteinising hormone-releasing hormone receptor.
Headquarters
Seattle, WA, US
Scorecard
All companies#790of 1706 companies, score 2
- modalities +2
0 approved, 0 in phase 3, 0 earlier, 0 targets, 0 registry studies. Formula on the scorecards page.
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI SBIR (R43) award 1R43CA306418-01A1: Stable, highly potent and safe lead peptide drug conjugate for the treatment of triple-negative breast cancer | 2026 | $400K | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Products
1PreclinicalPeptide drug conjugate
OTS-P22 is an experimental peptide drug conjugate from Oncotherapy Solutions, being prepared for triple-negative breast cancer and other solid tumours. It has not yet been tested in people.
Notes
- Company website (home and pipeline pages) and the NIH RePORTER record read on 4 November 2026. The website does not name the receptor OTS-P22 targets; the award abstract describes LHRH receptor conjugates, and whether OTS-P22 is one of them is not stated.
Connected
5Similar pages
cancers
fronts
technologies
drugs
PreclinicalPeptide drug conjugate
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
oncotherapysolutions.com · 2
nih.gov · 1
A source that has moved or gone is reported by the weekly link check. /audit/